Hostname: page-component-68945f75b7-fzmlz Total loading time: 0 Render date: 2024-08-06T10:19:16.958Z Has data issue: false hasContentIssue false
  • English
  • Français

‘Seroquel’®: A new option for the treatment of schizophrenia with no greater EPS than placebo

Published online by Cambridge University Press:  16 April 2020

J.S.E. Hellewell ,
G.A. Atkinson  and
J. McKellar
J.S.E. Hellewell
Affiliation:
Zeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, UK
G.A. Atkinson
Affiliation:
Zeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, UK
J. McKellar
Affiliation:
Zeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, UK

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Symposia
Information
European Psychiatry , Volume 13 , Issue S4: Standards of psychiatry - 9th Congress of Association of European Psychiatrists , 1998 , pp. 307s
Copyright
Copyright © European Psychiatric Association 1998
Submit a response

Comments

No Comments have been published for this article.